<DOC>
	<DOCNO>NCT03011333</DOCNO>
	<brief_summary>This Phase 2B , randomize , assessor-blind , active- saline placebo-controlled , multicenter study subject undergoing augmentation mammoplasty evaluate analgesic efficacy , safety , pharmacokinetics ( PK ) HTX-011 administered via ultrasound-guided lateral medial pectoral nerve block surgery .</brief_summary>
	<brief_title>Phase 2B Upper Extremity Nerve Block Study</brief_title>
	<detailed_description />
	<mesh_term>Bupivacaine</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<criteria>Each subject must meet follow criterion enrol study : 1 . Is able provide write informed consent , adhere study visit schedule , complete study assessment . 2 . Is female ≥18 year age . 3 . Is schedule undergo primary bilateral submuscular augmentation mammoplasty . 4 . Has American Society Anesthesiology ( ASA ) Physical Status I , II , III . 5 . Is able demonstrate motor function raise arm head unassisted . 6 . Is able assess sensory function exhibit sensitivity cold pectoral area ( upper outer quadrant ) . 7 . Subjects eligible follow apply : 1 . Not pregnant ( female subject childbearing potential must negative urine pregnancy test screening study drug administration ) . 2 . Not lactate . 3 . Not plan become pregnant study . 4 . Surgically sterile ; least 2 year postmenopausal ; monogamous partner surgically sterile ; practice doublebarrier contraception ; practice abstinence ( must agree use doublebarrier contraception event sexual activity ) ; use insertable , injectable , transdermal , combination oral contraceptive approve US Food Drug Administration ( FDA ) great 2 month prior screen commits use acceptable form birth control duration study 30 day study drug administration A subject meet follow criterion exclude study : 1 . Has plan concurrent surgical procedure . 2 . Has preexist concurrent acute chronic painful physical condition may require analgesic treatment postoperative period pain strictly relate augmentation mammoplasty may confound postoperative assessment . 3 . Has history hypersensitivity idiosyncratic reaction bupivacaine , amidetype local anesthetic , meloxicam . 4 . Has contraindication/known suspect hypersensitivity bupivacaine , meloxicam , oxycodone , morphine , hydromorphone ( eg , Dilaudid® ) . 5 . Has know suspect daily use opioids 7 consecutive day within previous 6 month . 6 . Has take longacting opioids within 3 day prior surgery , take opioids within 24 hour prior study drug administration . 7 . Has take bupivacaine local anesthetic within 72 hour prior study drug administration pretreatment prior needle placement . 8 . Has initiate treatment follow medication within 1 month study drug administration take medication control pain : selective serotonin reuptake inhibitor ( SSRIs ) , selective norepinephrine reuptake inhibitor ( SNRIs ) , gabapentin , pregabalin , duloxetine , cyclooxygenase2 ( COX2 ) inhibitor . If subject take one medication reason pain control , must stable dose least 1 month prior study drug administration . 9 . Has medical condition , opinion Investigator , participate study would pose health risk subject . Conditions may include follow : 1 . History clinically significant cardiac abnormality New York Heart Association class III IV , myocardial infarction , result significant clinical abnormality ECG function . 2 . Impaired kidney liver function . 3 . Chronic respiratory disease ( compromise function require regular bronchodilator treatment ) . 4 . Rheumatoid arthritis . 5 . Known suspect coagulopathy uncontrolled anticoagulation . 6 . Loss sensation extremity significant peripheral neuropathy . 10 . Has uncontrolled anxiety , psychiatric , neurological disorder might interfere study assessment 11 . Has chronic neuromuscular deficit either pectoral nerve function arm/shoulder/truncal musculature . 12 . Has chronic condition disease would compromise neurological vascular assessment . 13 . Had malignancy last year , exception nonmetastatic basal cell squamous cell carcinoma skin localize carcinoma situ cervix . 14 . Has know suspect history alcohol drug abuse , positive drug screen . 15 . Previous participation HTX011 study . 16 . Was administer investigational product within 30 day 5 elimination halflives ( whichever longer ) prior study drug administration , plan take another investigational product undergo another procedure subject 's participation study . 17 . Has body mass index ( BMI ) &gt; 35 kg/m2 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>